Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off from Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257). The former will provide the latter with services including DNA plasmid preparation, research into mRNA IVT stock solution technology, development of lipid nanoparticle (LNP) encapsulation process, production of mRNA IVT stock solutions and LNP encapsulation preparations. In addition, Innoforce will provide support in writing IND filings in China and the US in relation to RNAimmune’s mRNA research and development pipeline. No financial details were disclosed.
RNAimmune’s Technology and Focus
RNAimmune owns a proprietary peptide lipid nanoparticle (PLNP) technology platform for mRNA delivery, and is focused on the infectious disease, cancer, and rare disease fields.
Innoforce Pharma’s Services
Innoforce Pharma, meanwhile, is a biopharmaceutical innovation enabling platform and partner development and manufacturing organization (PDMO) providing end-to-end contract development and manufacturing organization (CDMO) services covering antibody and protein drugs.-Fineline Info & Tech
